| Fu, Siqing |
| Recruiting | 1/2 | 200 | Europe, US | HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C) | Hookipa Biotech GmbH, Hookipa Biotech | HPV-Related Squamous Cell Carcinoma | 06/25 | 06/26 | | |
NCT06385925: A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation |
|
|
| Recruiting | 1/2 | 150 | US | TSN1611 | Tyligand Bioscience (Shanghai) Limited | Malignant Neoplasm | 10/26 | 04/27 | | |
| Not yet recruiting | 1/2 | 20 | US | TTX-MC138 | TransCode Therapeutics | Advanced Solid Tumor | 02/26 | 02/27 | | |
KEYNOTE-D88, NCT05572684: A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 131 | US | NC410, pembrolizumab, KEYTRUDA® | NextCure, Inc., Merck Sharp & Dohme LLC | Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer | 07/25 | 11/25 | | |
NCT06056323: A Study of HB0045 Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 71 | US | HB0045 Drug Product, fixed dose combination of two antibodies targeting two different epitopes (N-terminal and catalytic site) of CD73 | Shanghai Huaota Biopharmaceutical Co., Ltd., Gabrail Cancer Center Research, Dana-Farber Cancer Institute, M.D. Anderson Cancer Center | Solid Tumor, Adult | 09/25 | 03/26 | | |
BA3021-001, NCT03504488: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) |
|
|
| Recruiting | 1/2 | 420 | Europe, US, RoW | CAB-ROR2-ADC, BA3021, PD-1 inhibitor | BioAtla, Inc. | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer | 12/25 | 12/25 | | |
NCT05036291: A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 120 | US | NB004 tablets, Sotorasib | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 02/25 | 06/25 | | |
NCT03646071: A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 80 | US | RX108 | NeuPharma, Inc. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 08/23 | 12/23 | | |
NCT04192344: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 85 | US | ABSK021 | Abbisko Therapeutics Co, Ltd | Neoplasms, Tenosynovial Giant Cell Tumor | 12/23 | 12/23 | | |
NCT05300438: Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. |
|
|
| Recruiting | 1 | 74 | US | TSN084 | Tyligand Bioscience (Shanghai) Limited | Cancer (With or Without Metastasis) | 03/25 | 06/25 | | |
NCT05704985: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors |
|
|
| Recruiting | 1 | 60 | US | DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Pembrolizumab, Nivolumab, Chemotherapy, Paclitaxel, Carboplatin, Oxaliplatin, Fluorouracil, Capecitabine | DEKA Biosciences | Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer | 09/24 | 02/25 | | |
GRN300-001, NCT04711161: First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. |
|
|
| Suspended | 1 | 73 | US | GRN-300, SIK2/3 Inhibitor, Paclitaxel, Taxane | Green3Bio, Inc. | Ovarian Tumors | 12/24 | 03/25 | | |
NCT05018273: Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors |
|
|
| Active, not recruiting | 1 | 60 | Europe, US | VB10.NEO, Atezolizumab, Tecentriq | Nykode Therapeutics ASA, Genentech, Inc., Vaccibody AS | Solid Tumors, Adult | 12/24 | 12/24 | | |
NCT05266612: Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 12 | US | VG2025, Nivolumab Injection [Opdivo] | Virogin Biotech Canada Ltd | Solid Tumor | 12/24 | 12/25 | | |
NCT05989724: A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 150 | US | SON-DP | Qurgen Inc. | Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer, Colorectal Cancer | 09/25 | 03/26 | | |
NCT06028373: A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas |
|
|
| Recruiting | 1 | 48 | US | ATG-031 | Antengene Biologics Limited | Advanced Solid Tumors, B-cell Non-Hodgkin Lymphomas | 12/25 | 06/26 | | |
NCT05075993: Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 352 | US | LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide | M.D. Anderson Cancer Center, Lyvgen Biopharma Holdings Limited | Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic HPV Related Solid Tumors, Metastatic Ovarian Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Uveal Melanoma | 02/27 | 02/27 | | |
